Illustrative image.
Semaglutide Compound
Semaglutide
$480.00
1mg/mL · 2 × 1 vial · 2 months supply
CompoundedCompounded medicine
$240.00 per month
Strength
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$2400a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
1mg/mL
5mg/mL
FDA boxed warningRisk of thyroid c-cell tumors
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC.
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
About Semaglutide Compound
Overview
Semaglutide Compound is a prescription medicine containing semaglutide, a GLP-1 receptor agonist. The supplied FDA label describes Ozempic, not this compounded product. That label includes use alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. Semaglutide works by helping the body release insulin and reducing glucagon release when blood sugar is high, while also slightly slowing stomach emptying after meals.
What it treats
The supplied Ozempic label lists use in adults with type 2 diabetes for: • Improving blood sugar control alongside diet and exercise. • Reducing the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke in those with established cardiovascular disease. • Reducing the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease.
Safety information
Side effects
The supplied Ozempic (semaglutide) label lists nausea, vomiting, diarrhea, abdominal pain and constipation as the most common side effects. Other reported effects include indigestion, burping, gas, acid reflux, tiredness, dizziness, altered taste and injection-site redness or discomfort. Serious side effects that warrant medical attention include: • Pancreatitis: persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting. Stop treatment and seek medical attention if pancreatitis is suspected. Cases have sometimes been fatal. • Serious allergic reactions, including anaphylaxis and swelling beneath the skin. Stop treatment and seek urgent medical help if an allergic reaction is suspected. • Low blood sugar, which may be severe, especially when used with insulin or medicines such as sulfonylureas. • Kidney injury, sometimes requiring dialysis, associated with dehydration from nausea, vomiting or diarrhea. • Severe digestive problems, including intestinal blockage and severe constipation with impacted stool. Contact a doctor for severe or persistent digestive symptoms. • Gallbladder problems, including gallstones and gallbladder inflammation. • Worsening diabetes-related eye disease. People with a history of diabetic retinopathy need monitoring. Semaglutide caused thyroid C-cell tumors in rodents; whether it causes these tumors in humans is unknown. Contact a doctor if you develop a neck lump, difficulty swallowing or breathing, or persistent hoarseness. Inhalation of stomach contents into the lungs has been reported during general anesthesia or deep sedation in people receiving this class of medicine. Tell healthcare providers that you use semaglutide before any planned surgery or procedure.
FDA boxed warning
Risk of thyroid c-cell tumors
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC.
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not use this medicine if you have a personal or family history of medullary thyroid carcinoma (MTC), a type of thyroid cancer, or multiple endocrine neoplasia syndrome type 2 (MEN 2). Do not use it if you have had a serious allergic reaction to semaglutide or any of the medicine’s ingredients. Semaglutide caused thyroid tumours in animal studies; whether it causes these tumours in humans is unknown. Report a neck lump, difficulty swallowing or breathing, or persistent hoarseness to your healthcare provider. Semaglutide is not recommended for people with severe gastroparesis (severely delayed stomach emptying). Tell your prescriber if you have diabetic retinopathy, as monitoring for worsening eye disease is needed, or if you have had a severe allergic reaction to another GLP-1 receptor agonist. Taking semaglutide with insulin or medicines that increase insulin release, such as sulfonylureas, increases the risk of low blood sugar, including severe episodes. Stop treatment and seek medical advice promptly if pancreatitis or a serious allergic reaction is suspected. Pancreatitis may cause persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting. Vomiting or diarrhoea can cause dehydration and kidney injury; kidney monitoring may be needed. Suspected gallstones or gallbladder inflammation require assessment. Tell your healthcare team about any planned surgery or procedure involving general anaesthesia or deep sedation because stomach contents may enter the lungs. Semaglutide should be stopped at least two months before a planned pregnancy.
Interactions
Using semaglutide with insulin or medicines that stimulate insulin release, such as sulfonylureas, can increase the risk of low blood sugar, including severe episodes. Your prescriber may need to adjust these medicines to reduce this risk. Semaglutide slows stomach emptying and may affect how medicines taken by mouth are absorbed. Clinical studies found no clinically relevant effect on absorption, but caution is still advised. Tell your doctor about any medicines you take by mouth.
Using Semaglutide Compound
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label OZEMPIC (SEMAGLUTIDE) INJECTION, SOLUTION [A-S MEDICATION SOLUTIONS] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Ozempic
Semaglutide
By NovoNordisk
Pen · from 1 per pack
Same active ingredient as Semaglutide Compound
Brand $249.00
Rybelsus
semaglutide
Tablets · from 30 per pack
Same active ingredient as Semaglutide Compound
Brand and generic from $120.00
Syringes for GLP-1
Syringes for GLP-1
Syringes · from 10 per pack
Also for diabetes
Pricing not listed yet
Mixtard 30/70
Insulin Human (30% Soluble Insulin, 70% Isophane Insulin)
By Novo Nordisk
Cartridge · from 5 per pack
Also for diabetes
Brand $82.00